Publications

Recent Approvals of Medicines Containing a New Active Ingredient

This article is more than five years old. Some content may no longer be current.

Prescriber Update 38(4):
December 2017

For period 16 July 2017 to 15 October 2017.

Trade Name (active ingredient)*	Dose Form and Strength	Therapeutic Area
Afluria Quad (influenza vaccine polyvalent)^†	Suspension for injection 60 µg/0.5mL	Influenza A & B immunisation
Elelyso (taliglucerase alfa)^†	Powder for injection 200 U	Type 1 Gaucher disease
Jaqinus (tofacitinib)^†	Film coated tablet 5 mg	Rheumatoid arthritis
Tagrisso (osimertinib)	Film coated tablet 40 mg and 80 mg	EGFR T790M mutation-positive non-small cell lung cancer

* New active ingredient shown in bold type
^† Not available

The data sheets for currently marketed prescription medicines are published on the Medsafe website (www.medsafe.govt.nz/Medicines/infoSearch.asp).